TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04160754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Relapse Prevention
Description: Individuals assigned to the experimental group will receive interventions normally provided at the clinic and eight 1.5-hour group sessions of MBRP. Each sessions will occur once per week and will target a specific theme such as being aware of personal triggers, maintaining present focus, allowing or letting things be, responding to emotional and physical experiences in skillful ways, and recognizing intrusive thoughts. Each session will incorporate a mindfulness meditation technique (e.g.,SOBER breathing space and urge surfing). Participants will receive materials (e.g., recordings) with which to perform practices and meditation during the intervention phase.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (CTL)
Description: Individuals assigned to the CTL group will receive interventions provided at the clinic and up to eight CTL sessions. The CTL group will receive information (reading) and videos once per week on health behaviors (e.g., exercise, eating) and the neurobiology of addiction. This approach will reduce the possibility that intervention effects are solely due to the experimental group's receiving extra attention. In contrast to the active intervention, sessions will be educational in nature, with no motivational, cognitive, or behavioral components
Study: NCT02945709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Attention control training (ACT)
Description: In this intervention, participants will be trained with a personalized Dot-Probe task. Each participant will perform the task with the set of words that he or she ranked as the most threatening according to a Word Ranking Task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-personalized Attention control training (ACT)
Description: In this intervention, participants will be trained with the same Dot-Probe task as in the personalized condition, except that the word stimuli will be randomly fit for each participant. It should be noted that 25% out of the words in this condition will be high ranked words according to each patient's word ranking. The aim of this is to enhance similarity to a generic ACT intervention (see Badura-Brack et al., 2015), where there is some degree of exposure to what one may consider personalized stimuli (i.e., threat words that were randomly included by the researchers), although it is not deliberately set to idiosyncratic preferences.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control training.
Description: In this intervention, participants will perform a computerized task, similar to the Dot-Probe task. In each trial, one neutral word will be presented at the center of the screen and participants will respond to a probe ('E' or 'f') presented following the removal of the words display. This version does not include the essential ingredients thought to reduce PTSD symptoms in the other dot-probe tasks: exposure to threat content and competition on attentional resources. Thus, this control version provides a control condition for the ACT interventions.
Study: NCT02110043

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: transcranial direct current stimulation (tDCS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: transcranial direct current stimulation (tDCS)

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: training
Description: intensive training of visual-spatial abilities (in LOCATO task)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training
Description: intensive training of visual-spatial abilities (in LOCATO task)
Study: NCT03041506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.~Lidocaine 2%: 15 -20 ml.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US guided ISCB
Description: Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.~Lidocaine 2%: 15 -20 ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: IV administration up to a maximum dosage of 0.1 mg/kg (bolus of 1 mg by titration every 30-60 seconds) for sedation and pain relief.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: IV administration up to maximum dosage of 100 mg IV (bolus of 25 mg by titration every 30-60 seconds) for sedation and pain relief.
Study: NCT00942994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren/Amlodipine
Description: Amlodipine capsule (5 mg)~Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)
Description: Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)~HCTZ capsule (12.5 mg, 25mg)
Study: NCT02583737

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: freeze bone allograft
Description: sinus lifting filling procedure employing freeze bone allograft from tissue bone bank.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lyophilized bone allograft
Description: sinus lifting filling procedure employing lyophilized bone allograft from tissue bone bank.
Study: NCT01386359

Intervention type: DRUG
Intervention: No Intervention
Description: No Intervention. Subjects are previously treated with Nulojix (belatacept)
Study: NCT02282943

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Vapourisation/excision of endometriosis AFS stages I-III using CO2 laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Description: Excision of endometriosis using Harmonic scalpel
Study: NCT00088374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17 allylamino-17-demethoxygeldanamycin
Description: 17 allylamino-17-demethoxygeldanamycin (17 AAG) given intravenously at a dose of 300 mg/m2 on days 1,8 and 15 of 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18 FDG (Fludeoxyglucose 18F)
Description: 18FDG PET performed at baseline and 12 weeks after treatment. At each timepoint participants can receive 250mCi 0-15 water and 15 mCi F18-FDG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [15-O] H2O
Description: \[15-0\] H20 performed at baseline and 12 weeks after treatment. At each time point participants can receive 250mCi 0-15 water and 15 mCi F18-FDG. The water scans were done as several intravenous injections for several scans but not over a total of 250 mCi.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPL diluent
Description: 17AAG is formulated with this diluent. Supplied in a 50 mL flint vial containing 48 mL of 2% egg phospholipids, and 5% dextrose in Water for Injection, USP. Patients with a history of serious allergic reactions to eggs should not receive this agent.
Study: NCT03730116

Intervention type: DRUG
Intervention: bisoprolol/perindopril FDC
Description: the first and only single-pill combination of beta-blocker and ACE inhibitor
Study: NCT02457637

Intervention type: OTHER
Intervention: Standary therapy
Description: Standary therapy for chronic liver disease with ALI and/or AD
Study: NCT01681264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guanfacine 1mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guanfacine 2mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guanfacine 2mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00987038

Intervention type: DRUG
Group type: OTHER
Intervention: PF-04171327 25 mg
Description: One 25 mg tablet administered once a day for 15 days

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam 2 mg
Description: Midazolam oral syrup 2mg dose administered once on Day 1 and once on Day 15
Study: NCT01201239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: RAL 400 mg twice daily plus OBT (optimized background therapy) for 48 weeks
Study: NCT02604277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal and Social Rhythm Therapy (ISRT)
Description: Interpersonal and Social Rhythm Therapy (ISRT) will be given once a week over a six week period for 55-60 minutes. ISRT emphasizes identifying and maintaining a regular routine in daily life. It includes addressing sleep and solving interpersonal concerns and conflicts by focusing on daily routine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bipolar-Specific Cognitive Behavioral Therapy (CBT)
Description: Bipolar-Specific Cognitive Behavioral Therapy (CBT) will be given once a week over a six week period for 55-60 minutes.The therapy is directly focused on eliminating or managing specific problems experienced by people with Bipolar Disorder. As part of this intervention, participant's maladaptive thoughts, behaviors and emotions are identified followed by learning how to challenge negative thoughts and reframing into positive, more adaptive thoughts. Additionally, the intervention involves enhancing the participant's coping skills and the ability to view a situation more objectively.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: Mindfulness-Based Stress Reduction (MBSR) will be given once a week over a six week period for 55-60 minutes. MBSR is a structured intervention that utilizes mindfulness meditation to reduce suffering associated with physical and psychiatric illnesses. MBSR is nonreligious in nature and aims to encourage an enhanced awareness of moment-to-moment experience of noticeable mental processes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-education & Understanding Bipolar Medications Therapy
Description: Psycho-education \& Understanding Bipolar Medications Therapy will be given once a week over a six week period for 55-60 minutes. Psycho-education \& Understanding Bipolar Medications Therapy aims to provide psycho-education about Bipolar Depression as well as provide a platform for participants to address concerns about managing their illness. Issues such as managing symptoms, reducing relapses and hospitalizations as well as maintaining gains will be discussed
Study: NCT04503278

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLDN6 CAR-T
Description: administered as an intravenous (i.v.) infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLDN6 CAR-T
Description: administered as an intravenous (i.v.) infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLDN6 uRNA-LPX/CLDN6 modRNA-LPX
Description: administered as an i.v. injection at protocol-specified intervals.
Study: NCT04499443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG131 tablets
Description: This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 10 mg, 30 mg, 60 mg, 100 mg, 150 mg, 200 mg, 250mg and 300 mg. Based on the results of a single dose, select 1 to 3 doses to conduct multiple dose studies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG131 tablets
Description: This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 10 mg, 30 mg, 60 mg, 100 mg, 150 mg, 200 mg, 250mg and 300 mg. Based on the results of a single dose, select 1 to 3 doses to conduct multiple dose studies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG131 tablets
Description: This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 10 mg, 30 mg, 60 mg, 100 mg, 150 mg, 200 mg, 250mg and 300 mg. Based on the results of a single dose, select 1 to 3 doses to conduct multiple dose studies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG131 tablets
Description: This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 10 mg, 30 mg, 60 mg, 100 mg, 150 mg, 200 mg, 250mg and 300 mg. Based on the results of a single dose, select 1 to 3 doses to conduct multiple dose studies.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 10 mg, 30 mg, 60 mg, 100 mg, 150 mg, 200 mg, 250mg and 300 mg. Based on the results of a single dose, select 1 to 3 doses to conduct multiple dose studies.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 10 mg, 30 mg, 60 mg, 100 mg, 150 mg, 200 mg, 250mg and 300 mg. Based on the results of a single dose, select 1 to 3 doses to conduct multiple dose studies.
Study: NCT03705728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be automatically administered according to the EasyTIVA device algorythm to maintain the BIS value within the 40-60 interval

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane will be manually administered to maintain the BIS value within the 40-60 interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil automatic
Description: Remifentanil will be automatically administered according to the EasyTIVA device algorythm to maintain the BIS value within the 40-60 interval

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil manual
Description: Remifentanil will be manually administered to maintain the BIS value within the 40-60 interval
Study: NCT00872807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling in groups
Description: The activity school in Finnmark. Lifestyle counseling (physical activity and dietary modification) in groups both at the hospital and in their own municipality.~They meet a multidisciplinary team, receive organized physical activity in the municipality and are invited to a 3 days camp after 4-6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual intervention
Description: Conventional lifestyle counseling individually by single health professionals, both in hospital and in municipality.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual intervention
Description: Conventional lifestyle counseling individually by single health professionals, both in hospital and in municipality.
Study: NCT02385630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized 400kcal semi-liquid meal
Description: Used to assess post-prandial gut hormone response pre-operatively and at 10 days, 4 weeks, 6 months and 12 months post-operatively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized 400kcal semi-liquid meal
Description: Used to assess post-prandial gut hormone response pre-operatively and at 10 days, 4 weeks, 6 months and 12 months post-operatively.
Study: NCT04539210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Welded Metal Framework
Description: Screw-retained Maxillary Complete Denture With Electric Welded Metal Framework

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Welded Metal Framework
Description: Screw-retained Maxillary Complete Denture With Electric Welded Metal Framework
Study: NCT02358642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitor (Lisinopril)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01745770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine - TID 1000 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine - TID 2x 500 mg
Study: NCT03861754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Study: NCT02408471

Intervention type: DEVICE
Group type: OTHER
Intervention: Ascension® MCP Finger Implant
Description: Patients who meet inclusion/ exclusion criteria are treated with the Ascension® MCP.
Study: NCT02594306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emotional pictures stimulation system
Description: Emotional pictures stimulation system is component of neutral and drug-related images.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emotional pictures stimulation system
Description: Emotional pictures stimulation system is component of neutral and drug-related images.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Emotional pictures stimulation system
Description: Emotional pictures stimulation system is component of neutral and drug-related images.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Deep brain stimulation of bilateral NAc/ALIC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjacent contact stimulation
Description: The electrode of deep brain stimulation has four contacts.We stimulate one contact,and record the local field potential of other contacts.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microelectrode
Description: We put the microelectrodes into bilateral nucleus accumbens and anterior limb of the internal capsule,to record the waveform of bilateral NAc/ALIC.
Study: NCT03685266

Intervention type: OTHER
Intervention: Observation
Description: There are no specific interventions in this study; it is observational only. One could argue that the act of observing the participants may change their behavior (the Hawthorne effect).
Study: NCT01740375

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophagectomy
Description: esophagectomy
Study: NCT03254420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calypso beacon implant
Description: Calypso beacon implant before radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: moderate hypofractionation Radiotherapy
Description: moderate hypofractionation Radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: moderate hypofractionation Radiotherapy
Description: moderate hypofractionation Radiotherapy
Study: NCT03205462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorothyazinone 300 mg
Description: Fluorothyazinone in a dosage of 300 mg (1 tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorothyazinone 600 mg
Description: Fluorothyazinone in a dosage of 600 mg (2 tablets) is received per os (oral administration) as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorothyazinone 3900 mg
Description: The total dose of Fluorothyazinone per treatment course is 3900 mg.
Study: NCT03169985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day
Description: After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months by clinical judgement.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20 mg orally once a day
Description: After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months based by clinical judgement.
Study: NCT00858858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: 8 weeks of oral UDCA treatment 10 mg/kg qd
Study: NCT01547455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin(Lipitor)
Description: participants take 80mg Atorvastatin orally 12h before surgery with another 40mg 2h before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to Control arm take 80mg placebo 12h before surgery with another 40mg 2h before surgery
Study: NCT00264238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: pharmacological dosing of memantine as adjunctive therapy for treatment-resistant obsessive-compulsive disorder
Study: NCT06491758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abvn
Description: A modality of therapy currently being utilized to treat focal or partial seizures that do not respond to seizure medications is called as VNS Therapy (Vagus Nerve Stimulation). This has been approved by FDA as an effective treatment for seizure disorders. Our aim is to study the HRV in patients undergoing this therapy as part of their regular mode of treatment. The specific aim is to measure the HRV in patients undergoing vagus nerve stimulation therapy.~During VNS treatment the stimulator is surgically implanted in the upper chest and stimulation electrodes are implanted in the left cervical vagus nerve.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PENFS- Percutaneous Electrical Nerve Field Stimulation
Description: PENFS- Percutaneous Electrical Nerve Field Stimulation (PENFS) has been shown to be an effective treatment for abdominal pain in adolescent patients with irritable bowel syndrome (1). The mechanism is unclear. PENFS is thought to stimulate branches of several cranial nerves in the external ear (V, VII, IX and X) that project to the brainstem. However, the mechanism responsible for the clinical effect is unclear and speculative. We propose to determine whether PENFS 1) stimulates the vagus nerve and produces measurable vagus nerve compound actions potentials, 2) causes changes in parasympathetic and sympathetic nerve activity, and 3) produces changes in the human electrogastrogram (EGG).
Study: NCT01806779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chantix

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chantix
Study: NCT06491758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wrist worn Corsano Cardio Watch 287-2B)-
Description: Use of wearable device (wrist worn Corsano Cardio Watch 287-2B)- It will be used in the next phase to gather critical data that describe the study participant physiology during their normal daily activities (Fig 1A). Wearable-sensor derived biometrics that describe changes in heart rate, respiration rate, blood oxygen saturation, noninvasive blood pressure, physical activity, electrodermal activity (EDA), and sleep will be paired with daily symptom diaries and weekly surveys to assess quality of life and autonomic dysfunction (Fig 1B). The aim is to capture the nature, type, frequency, and severity of common EDS symptoms, such as posture-related tachycardic or hypotensive events, sleep disturbances, musculoskeletal pain, severe fatigue, and gastrointestinal distress.